Clicky

Calliditas Therapeutics(CALTX)

Description: Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease. It also develops Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis. The company was incorporated in 2004 and is headquartered in Stockholm, Sweden.


Keywords: Medicine Biopharmaceutical Chemical Compounds Autoimmune Disease Hepatitis Liver Disease Chloroarenes Idiopathic Pulmonary Fibrosis Head And Neck Cancer Hepatology Primary Biliary Cholangitis Squamous Cell Carcinoma Diabetic Kidney Disease Autoimmune Hepatitis Nefecon Pharmaceuticals Products

Home Page: www.calliditas.se

Kungsbron 1, D5
Stockholm, 111 22
Sweden
Phone: 46 84 11 30 05


Officers

Name Title
Ms. Renee Aguiar-Lucander Chief Exec. Officer
Mr. Fredrik Johansson Chief Financial Officer
Dr. Katayoun Welin-Berger Ph.D. VP of Operations
Dr. Johan Haggblad Ph.D. Chief Scientific Officer
Mr. Mikael Widell Head of Communications & IR
Mr. Jonathan A. Schur Group Gen. Counsel
Ms. Sandra Frithiof Head of HR
Ms. Ann-Kristin Myde BSc Head of Clinical Devel. & VP of Project Management
Mr. Andrew B. Udell B.Sc., M.B.A. Pres of North America Commercial
Dr. Krassimir Mitchev Head of Medical Affairs

Exchange: ST

Country: SE : Sweden

Currency: Swedish krone (kr)

Forward PE: 8.8261
Trailing PE: 0
Price-to-Book MRQ: 7.4307
Price-to-Sales TTM: 12.9805
IPO Date:
Fiscal Year End: December
Full Time Employees: 98
Back to stocks